Protocol

The Facilitation of Clinical and Therapeutic Discoveries in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Related Diseases: Protocol for the You + ME Registry Research Platform

Allison Ramiller, BSc, MPH; Kathleen Mudie, BSc, MSc; Elle Seibert, BA; Sadie Whittaker, DPhil
Solve ME/CFS Initiative, Glendale, CA, United States

Corresponding Author:
Allison Ramiller, BSc, MPH
Solve ME/CFS Initiative
Suite B #368 Glendale
350 N Glendale Ave
Glendale, CA, 91206
United States
Phone: 1 704 364 0016
Email: research@solvemefs.org

Related Article:
This is a corrected version. See correction statement in: https://www.researchprotocols.org/2022/10/e42030

Abstract

Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic, complex, heterogeneous disease that affects millions and lacks both diagnostics and treatments. Big data, or the collection of vast quantities of data that can be mined for information, have transformed the understanding of many complex illnesses, such as cancer and multiple sclerosis, by dissecting heterogeneity, identifying subtypes, and enabling the development of personalized treatments. It is possible that big data can reveal the same for ME/CFS.

Objective: This study aims to describe the protocol for the You + ME Registry, present preliminary results related to participant enrollment and satisfaction, and discuss the limitations of the registry as well as next steps.

Methods: We developed and launched the You + ME Registry to collect longitudinal health data from people with ME/CFS, people with long COVID (LC), and control volunteers using rigorous protocols designed to harmonize with other groups collecting data from similar groups of people.

Results: As of September 30, 2021, the You + ME Registry had over 4200 geographically diverse participants (3033/4339, 69.9%, people with ME/CFS; 833/4339, 19.2%, post–COVID-19 people; and 473/4339, 10.9%, control volunteers), with an average of 72 new people registered every week. It has qualified as “great” using a net promotor score, indicating registrants are likely to recommend the registry to a friend. Analyses of collected data are currently underway, and preliminary findings are expected in the near future.

Conclusions: The You + ME Registry is an invaluable resource because it integrates with a symptom-tracking app, as well as a biorepository, to provide a robust and rich data set that is available to qualified researchers. Accordingly, it facilitates collaboration that may ultimately uncover causes and help accelerate the development of therapies.

Trial Registration: ClinicalTrials.gov NCT04806620; https://clinicaltrials.gov/ct2/show/NCT04806620

International Registered Report Identifier (IRRID): DERR1-10.2196/36798

(JMIR Res Protoc 2022;11(8):e36798) doi: 10.2196/36798

KEYWORDS

myalgic encephalomyelitis/chronic fatigue syndrome; long COVID; data acquisition source; postinfectious; longitudinal cohort study; patient powered; COVID-19; chronic fatigue syndrome; longitudinal health data; symptom-tracking app; health application; mobile health; digital health
Introduction

Background to ME/CFS
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic, complex, systemic disease that affects anywhere from 1.5 to 3.4 million people in the United States [1,2], with an estimated annual economic cost of US $36-$51 billion [2]. The etiology of ME/CFS is unknown, but it is associated with infectious triggers or other precipitating events, such as injury, trauma, or exposure to environmental hazards [3]. ME/CFS has not been correlated with age, race, or socioeconomic group; however, 3-4 times as many women as men present with symptoms [3].

The true impact of this disease remains uncertain largely because ME/CFS is commonly misdiagnosed, with primary reasons referenced as a lack of confidence from clinicians and the absence of an established biomarker [4]. Clinicians must rely on a detailed evaluation of the presence of characteristic symptoms, health history, and a physical examination. Although many clinicians are aware of ME/CFS, they often lack essential experience necessary to diagnose this complex disease.

ME/CFS is characterized by debilitating fatigue and other multisystem physical and neurocognitive symptoms, which are exacerbated following minimal physical or mental exertion. Postexertional malaise (PEM) is the hallmark symptom of ME/CFS and is associated with elevated symptom burden and psychological distress [3]. Otherwise, substantial clinical heterogeneity exists among patients, with a range of symptoms that includes orthostatic intolerance (OI), postural tachycardia syndrome (POTS), brain fog, headaches, unrefreshing sleep and other sleep dysfunction, joint pain, and muscle pain/fibromyalgia [3].

Although understanding of biological abnormalities in ME/CFS has increased considerably in recent decades [5-10], the lack of a diagnostic biomarker, complex clinical presentation, and patient heterogeneity have severely hampered progress in the treatment of ME/CFS, causing many patients to have poor outcomes [3,11]. Although there are no treatments approved for ME/CFS, a number of pharmacological and nonpharmacological interventions are used to manage symptoms. There have been a few promising clinical trials undertaken; however, they have not resulted in approved therapies for the ME/CFS population. For example, researchers analyzing data from a phase III trial of rintatolimod found that only a subset of ME/CFS patients defined by relatively short duration of disease (symptom onset within 2-8 years) had improved exercise tolerance in response to rintatolimod [12]. Although this is still an experimental treatment, there is an acute interest in identifying subsets of patients who might be responders [12,13].

Methodological problems, small sample sizes, and selection bias toward those less severely affected by ME/CFS [14] also create persistent roadblocks to progress in the understanding of the disease. An observational study that centralizes clinical data and well-designed patient-reported outcomes collected over time from a large, diverse cohort has the potential to increase research validity and generate new insights.

The You + ME Patient Registry
Patient registries are invaluable resources for collecting real-world clinical data at a large scale that can then be used for research. They comprise a set of systematically collected and stored data that can be harmonized or shared with other research groups, while ensuring a level of data quality and reliability. Patient registries have been effectively used for other complex, heterogenous diseases, such as the Fox Insight study for Parkinson disease [15]; the IBD Partners Registry [16], where IBD refers to inflammatory bowel disease; and ACCELERATE, an international registry for patients with Castleman disease [17].

In May 2020, the Solve ME/CFS Initiative (Solve M.E.), a nonprofit organization whose mission is to make ME/CFS and other postinfection diseases widely understood, diagnosable, and treatable, launched the You + ME Registry and Biobank (Registry) [18]. The Registry is a secure online data repository where people with ME/CFS, people with related diseases, and control volunteers can enter information on their health.

Given the strong evidence for the viral etiology of ME/CFS and experience from the SARS-CoV-1 pandemic of 2003 [19-21], there is a potential for the current SARS-CoV-2 pandemic to lead to a substantial increase in the number of ME/CFS cases. There is evidence that some people experience long-term effects from COVID-19 (termed “long COVID” [LC]) with a constellation of symptoms reported that are strikingly similar to those reported for ME/CFS [22-27]. The COVID-19 pandemic and emergence of long-term symptoms in some individuals present a unique scientific opportunity to understand factors of resistance and susceptibility to long-term, postviral impacts. In December 2020, in response to the increasing number of individuals with LC, the Registry was adapted and opened up to those who are suffering from the long-term effects of COVID-19 and control individuals who had COVID-19 but do not have long-term effects.

The Registry is designed to be a foundational resource for research, and it is unique for several reasons:

- It integrates a symptom-tracking app that can provide more data points for dynamic/cyclic chronic diseases.
- It is a rigorous, systematic infrastructure for collecting data that were cocreated with the ME/CFS and LC communities.
- The data and patient cohorts are available to all qualified researchers, supporting numerous scientific studies and engaging a network of expertise.
- The Registry is centered around principles of data harmonization and collaboration with other research studies to accelerate the search for causes and therapies.

In this paper, we describe the protocol for the Registry, present preliminary results related to participant enrollment and satisfaction, and discuss the limitations of the Registry as well as next steps.
Methods

Human-Centered Design

The creation of the Registry integrated community input and human-centered design (HCD) methodologies [28]. Originally developed in the field of computer science and artificial intelligence, it has been adapted so that engagement with and understanding of the needs of users are common to all design disciplines and can be applied to a range of complex questions, from process optimization to product design [29-31]. We gathered qualitative narratives and quantitative data from multiple stakeholders to inform the Registry and symptom-tracking app product development, user experience, and data collection.

One-on-one unstructured phone interviews were conducted with stakeholders and experts. Interviewees included 4 people with ME/CFS across the disease severity spectrum, 1 care partner, and 3 individuals with expertise in disease registries, informatics, and HCD. Notes from the calls were transcribed and summarized into key themes and insights (Table 1).

Table 1. Key insights from HCD interviews with the ME/CFS community.

| Category of expertise                        | Key insights                                                                 |
|---------------------------------------------|-----------------------------------------------------------------------------|
| People with ME/CFS                          | • Elevate individuals with ME/CFS to partner/contributor status.            |
|                                             | • Create mechanisms that will enable participation and insights for people   |
|                                             |   with severe ME/CFS.                                                      |
|                                             | • Include measures that will corroborate or add on to the symptom data,    |
|                                             |   including a measure to assess functional status.                        |
| ME/CFS clinicians and researchers           | • Ensure collection of information on autonomic function.                  |
|                                             | • Track regularly whether the person's medications have changed and whether |
|                                             |   they have been diagnosed with new conditions/diseases.                  |
| Informatics                                 | • Foster a social component because people who engage socially are more     |
|                                             |   likely to continue to enter data.                                        |
|                                             | • Provide the ability for participants to report quantified self-data and   |
|                                             |   self-experiment (eg, supplements and medications being used).           |
| HCD                                         | • Consider more innovative approaches to enable participation of extremes  |
|                                             |   in your patient population.                                             |
| Informal caregiver                          | • Create a formal, defined user group involved throughout the cycle of the |
|                                             |   process.                                                                 |
| Community relations expert                  | • Partner with advocacy groups for the community, both national and local  |
|                                             |   chapters.                                                               |
|                                             | • Create an advisory board including active patient advocates to review    |
|                                             |   proposals for research.                                                  |

aHCD: human-centered design.
bME/CFS: myalgic encephalomyelitis/chronic fatigue syndrome.

An online survey collected anonymous perspectives from 251 people with ME/CFS regarding symptoms they experience, the method/frequency of data capture that would work best, and how data should be reported back through a mobile app. The results were compared to a community survey developed by collaborators at Columbia University (unpublished), for a combined response set from over 1200 people with ME/CFS.

Symptoms endorsed by most of the survey respondents (ie, fatigue, PEM, cognitive impairment, unrefreshing sleep) were included in a core set of symptoms that autopopulate for app users. However, community feedback made it clear that capturing a complete range of symptoms would be critical for relevancy of the app to the individual, so we included the ability to add custom symptoms. Although most said they would use the app daily or weekly, about one-third indicated this was too frequent.

To accommodate variation in disease severity and function, we set up the app to allow data capture as often as daily and included communications every 3 days to encourage data entry. We also added screens to track activities (eg, work, social, leisure) in the first build of the mobile app because respondents were highly interested in understanding the links between activities and symptoms.

Over 30 individuals tested a beta version of the registration process and tracking app on their Apple and Android phones—including people with ME/CFS, care partners, researchers, and clinicians. Most beta testers used a template form to provide feedback with yes/no options, numerical ranking scales, and open comment fields. Version 2.0 of the app was developed in response to tester input with enhanced user guidance and prompts, the ability to add narratives through a journal screen, and the addition of a calendar functionality. When the Registry was adapted and opened for the post–COVID-19 cohort, we utilized a similar community testing and feedback process. The user experience and data collection are continuously improved based on feedback from patients and researchers.

Technical Infrastructure

The Registry data are securely stored in an encrypted database hosted in a cloud-based instance [32]. The database stores data records as documents, which are collated into collections (analogous to tables in a relational database) and linked according to unique identifiers. Participant data are encrypted.
in transit using industry-standard Transport Layer Security/Secure Socket Layer to protect sensitive information when it is transmitted to and from the front-end apps and backend database. Amazon Cognito is used for user authentication and access control. Strict security and access standards are in place to protect participant data.

The Registry is designed to be a globally shared repository that removes data silos and increases collaboration. The digital tools and services that comprise the registry are setup for Health Insurance Portability and Accountability Act (HIPAA) and General Data Protection Regulation (GDPR) compliance to ensure the highest international standards of data privacy are met and to allow enrollment and collection of self-report survey data from participants worldwide. We plan to work with local partners to ensure regional data privacy and regulatory requirements are fulfilled for the collection of future data types (eg, health care data, biological samples).

**Data Harmonization**

The validated data collection instruments within the Registry (see the Data Collection section) are aligned with those used by other researchers and clinicians studying patients with ME/CFS. They include the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) Common Data Elements [33] to facilitate aggregation of data across studies. After consulting with community members, additional data fields were included to build a richer understanding of each participant’s health history. The Registry also integrates the NINDS centralized Globally Unique Identifier (often referred to as GUID) solution, a secure tool that generates unique IDs without exposing personally identifiable information (PII) to allow data sharing and collaboration across research groups.

**Participant Recruitment**

The Registry is open to all individuals with ME/CFS, those with LC, and other populations, including individuals with other chronic diseases and individuals considered healthy controls. The aim is to enroll a diverse global cohort of participants who are representative of the broader ME/CFS and LC communities and to create the largest-possible global data set to interrogate.

The Registry is promoted via Solve M.E.’s and You + ME’s dedicated @youmeregistry social media channels (Facebook, Twitter, Instagram), on a dedicated online informational website [18], printed newsletters, and email to the Solve M.E. listserv. It is also promoted in webinars and conference presentations.

Additional recruitment is conducted through partners in both ME/CFS and LC by leveraging their social media channels and email listservs. This is particularly important for recruitment to our ME/CFS and LC cohorts, given that many in these communities are connected via robust social media groups [34]. Our LC recruitment strategy specifically is multipronged (Table 2). Outreach is focused on areas with historically high incidences of COVID-19 cases (eg, New York City, New Orleans, and Los Angeles). Future plans for recruitment include referrals from clinicians and health systems.

**Table 2.** Overview of current and planned recruitment strategies for the Registrya.

| Type of outreach                          | Target organizations/partners and strategy |
|------------------------------------------|------------------------------------------|
| Solve M.E.b communication channels       | Promote the Registry to our established network via (1) a database of over 34,000 active contacts; (2) organizational and Registry social media accounts with a combined following of 6772 on Twitter, 34,114 on Facebook, and 2256 on Instagram; and (3) our educational webinar series for researchers, clinicians, and patients. |
| COVID-19 survivor postacute sequelae of COVID-19 (PASC) patient groups | Partner with established groups serving COVID-19 survivors and individuals with PASC, including online forums and support groups on social media, to promote the Registry to their networks. |
| LCc alliance                             | Partner with members to create a referral pipeline to the Registry from over 50 science, postviral disease, and patient advocacy and research organizations working together to find answers for LC and postviral illness. |
| Internet and social media advertising    | Google Ads and social media posts directed toward individuals who have experience in COVID-19 and primary care providers who may be treating those with persistent symptoms of COVID-19. |
| Clinics/health systems                    | Partner with health systems, clinics, and hospitals serving our populations of interest to provide a postcard that will be handed out to their patients with COVID-19. The postcard will ask about the development of persistent postviral symptoms and direct patients to the Registry for voluntary sign-up. |
| Membership organizations/trade associations | Partner with health care workers and emergency medical services (EMS) unions; other unionized or nonunionized essential workers, such as large grocery/drug store chains, transit workers, and delivery services; university-based, countrywide student organizations, athletic associations. and student health networks; and medical specialty associations to share the recruitment notices to their membership. |

---

*aRegistry: You + ME Registry and Biobank.
*bSolve M.E.: Solve ME/CFS Initiative, where ME/CFS refers to myalgic encephalomyelitis/chronic fatigue syndrome.
*cLC: long COVID.

**Criteria for Selection**

The Registry is open to individuals of all genders, with an anticipated gender split between males and females reflective of the gender prevalence of ME/CFS and LC. Adults (aged 18 years and above) are eligible for participation. All races and ethnic origins are included. Although we do not limit enrollment from control volunteers, we will be making every effort to ensure controls are adequately matched to patients by age, sex, race, and other key demographic indicators.
People With ME/CFS

People with ME/CFS self-diagnosed or diagnosed by a clinician are eligible to enroll. Many patients with ME/CFS struggle for years before being diagnosed; it has been estimated that up to 90% of people with ME/CFS have not received an official diagnosis from a clinician [35,36]. Rather than exclude participants based on a lack of clinical diagnosis at enrollment, we include these individuals and record the method of diagnosis for each participant. We also have a recurring question about clinician diagnosis to track any changes.

People With COVID-19

People who had COVID-19, whether confirmed or not confirmed by a lab test, are eligible to enroll. Access to and reliability of COVID-19 lab tests caused difficulties to confirm an infection, particularly in the early period of the pandemic. Therefore, we allow self-reporting of COVID-19 infection and record the method of initial COVID-19 diagnosis for each participant.

Control Volunteers

Control volunteers are made up of individuals without ME/CFS or LC, including individuals considered healthy controls and those with other chronic illnesses (eg, fibromyalgia).

Symptom Assessment and Algorithm for ME/CFS Case Criteria

For all participants, the Registry scores responses to the UK ME/CFS Biobank (UKMEB) Symptoms Assessment Questionnaire to determine fulfillment of distinct ME/CFS case criteria [37], including the CDC-1994 (Fukuda) criteria [38], the Canadian Consensus criteria [39], the International Consensus criteria [40], the Institute of Medicine criteria [41], and the Oxford criteria [42]. This is to align with what has been proposed for use in clinical practice and currently being used by ME/CFS researchers worldwide [43]. Questionnaire responses are fed to a digitized version of the algorithm licensed from the UKMEB to the Registry, which is coded into the online platform in a separate endpoint that securely runs the data for scoring.

Data Collection

Participants sign up for the Registry via a secure website interface. Participants are asked to complete an electronic informed consent form for collection of data and to be recontacted for optional biosample collection or other study opportunities. After consenting to the Registry, they are guided through a series of baseline surveys (Table 3), including medical history, diagnosed conditions, symptoms and quality of life, and medication history.
### Table 3. Surveys used in the Registry and what they measure.

| Survey                        | Measures                                                                 |
|-------------------------------|--------------------------------------------------------------------------|
| ME/CFS Disease History        | Disease-specific history (triggers, onset, disease course)               |
| COVID-19 History              | Infection status, acute illness, clinical course                          |
| UKMEB Symptoms Assessment     | Symptom experience and fulfillment of ME/CFS case definitions             |
| Short Form-36                 | Health-related quality of life                                           |
| Karnofsky Performance Status  | Functional status                                                        |
| Multidimensional Fatigue Inventory | General fatigue, physical fatigue, reduced motivation, reduced activity, and mental fatigue |
| Demographics                  | Diagnosed conditions                                                     |
| My Conditions                 | Medications, supplements, and other treatments                           |
| My Treatments                 | Information about disorders from which a direct blood relative may or may not have suffered |
| Family Health History         | A screening tool for hypermobility                                        |
| Beighton Score                | Physical functioning, work status, depression, anxiety, morning tiredness, pain stiffness, fatigue, and well-being |
| Fibromyalgia Impact Questionnaire Revised | Vaccination status, symptoms (pre-existing and following the vaccine), and reasoning for not getting vaccinated (if indicated) |
| COVID-19 Vaccination Status   |                                                                           |

---

aRegistry: You + ME Registry and Biobank.
bME/CFS: myalgic encephalomyelitis/chronic fatigue syndrome.
cThe survey is only presented to those who indicate they have ME/CFS.
dA one-time survey.
eThe exact same questionnaire asked at follow-up timepoints.
fUKMEB: UK ME/CFS Biobank.
gAbbreviated/modified version of the questionnaire asked at follow-up timepoints.
hA form that can be revised/added to on an ongoing basis.
iThe survey is only presented to those who indicate they have fibromyalgia.

Longitudinal characterization is imperative to understanding chronic illnesses that are evolving and have a cyclical nature. Volunteers with ME/CFS and control volunteers are sent email reminders to complete an abbreviated set of surveys every 90 days following registration (Figures 1 and 2). We hypothesize that biologically or clinically distinct factors drive divergent outcomes in post–COVID-19 patients toward complete recovery or long-term sequelae. So, the post–COVID-19 cohort is sent follow-up surveys every 30 days in the initial 6 months and then every 90 days for longer-term follow-up (Figure 3). Through more frequent data collection during this critical period following recent infection, we aim to identify factors driving or predictive of this bifurcation in outcomes.
**Figure 1.** Overview of the first 6 months of longitudinal Registry data collection, which includes electronic surveys administered at enrollment (baseline) and follow-up time intervals in adults with ME/CFS. Individuals with ME/CFS can opt to track their symptoms using a numerical scale from 0 (symptom absent) to 4 (very severe) in a mobile app. Severity scores are defined as follows, according to the DePaul Symptom Questionnaire: 0=symptom not present, 1=mild, 2=moderate, 3=severe, 4=very severe. ME/CFS: myalgic encephalomyelitis/chronic fatigue syndrome; Registry: You + ME Registry and Biobank.

**Figure 2.** Overview of the first 6 months of longitudinal Registry data collection, which includes electronic surveys administered at enrollment (baseline) and follow-up time intervals in adult control volunteers. ME: myalgic encephalomyelitis; Registry: You + ME Registry and Biobank. SF-12: 12-item Short Form Survey; SF-36: 36-item Short Form Survey.
Figure 3. Overview of the first 6 months of longitudinal Registry data collection, which includes electronic surveys administered at enrollment (baseline) and follow-up time intervals in adults post–COVID-19. Individuals can opt to track their symptoms using a numerical scale from 0 (symptom absent) to 4 (very severe) in a mobile app. Severity scores are defined as follows, according to the DePaul Symptom Questionnaire: 0=symptom not present, 1=mild, 2=moderate, 3=severe, 4=very severe. ME: myalgic encephalomyelitis; Registry: You + ME Registry and Biobank. SF-12: 12-item Short Form Survey; SF-36: 36-item Short Form Survey.

One-time questionnaires are also deployed through the Registry, in addition to the regular longitudinal assessments. These questionnaires collect cross-sectional data from unique instruments that are not part of the routine longitudinal assessments, and currently include surveys on family health history, joint hypermobility (self-report Beighton), and COVID-19 vaccination experience.

Data are aggregated into a single table and are available as a comma-separated value file. Values of variables are encoded according to a data dictionary, which accompanies each data file and describes the metadata available for each survey question in the routine longitudinal assessment and one-time surveys. The complete data dictionary includes over 800 collected variables and is available upon request.

Symptom Tracking

Upon completion of the first set of surveys, participants are sent an email with a link to download the You + ME symptom-tracking mobile app. The symptom-tracking app allows individuals with ME/CFS, LC, and other chronic diseases to record symptoms, lifestyle factors, life events, and any activities on an ongoing basis (Figures 4-6).
Figure 4. Using the mobile app tracking screen, users can report the presence and severity of symptoms felt.

Figure 5. Using the mobile app tracking screen, users can log which treatments were taken that day. ME/CFS: myalgic encephalomyelitis/chronic fatigue syndrome.
Data Management
The principal investigator is responsible for overseeing data quality and reliability and ensuring safeguards are in place to protect participant privacy and safety. The Registry data manager audits the data biweekly to improve quality, ensure validity and reliability, and guarantee the integrity and credibility of output.

Data Sharing
Researchers who want to access the data for research apply to Solve M.E. with information required to review their request, including their name, institution, terminal degree, relevant publications, and research interest. The application is reviewed by the You + ME Innovation Council, a group of approximately 12 individuals with deep expertise in ME/CFS and chronic disease research or data science (clinicians, researchers, data scientists, and individuals with ME/CFS and other chronic diseases). Data are stripped of identifiers and shared with researchers through secure means of transfer. Researchers who use the data are required to sign a data use agreement that includes a guarantee to share their methods and findings with the ME/CFS and LC patient communities.

Ethical Considerations
The Registry was approved and is overseen by the Western Institutional Review Board (Protocol #20193104).

Results
Participant Enrollment
As of September 30, 2021, the Registry had over 4200 participants: 3033/4339 (69.9%) people with ME/CFS, 833/4339 (19.2%) post–COVID-19 people, and 473/4339 (10.9%) control volunteers. Recruitment to the Registry continues at a steady pace, with an average of 72 new people registered every week, responding to social media and other outreach efforts.

The Registry includes participants from all 50 states of the United States (see Figures 7 and 8). Participant-provided zip codes matched to rural-urban commuting area codes from the 2010 Census indicate that 256/2085 (12.3%) of ME/CFS and 42/387 (10.9%) of LC registrants who provided zip code data live in nonurban areas. The Registry is open to LC registrants internationally. The highest concentration of LC registrants is in the United States (n=651, 78.2%), the United Kingdom (n=44, 5.3%), and Canada (n=72, 8.6%); in total, there is representation from 32 countries (see Figure 9).

Although a major goal of the Registry is to open up participation in research to underrepresented groups, enrollment to date is largely consistent with previous ME/CFS research cohorts. The male-to-female sex ratio for the entire Registry cohort is 23:100, meaning for roughly every 23 males, there are 100 females (intersex individuals make up 0.001% of the participants). Registry participants are predominantly non-Hispanic White. An area of divergence from most previous studies is the significant proportion of individuals in the Registry who are severely-to-very-severely ill, including nearly one-third (581/1096, 30.5%) of our ME/CFS cohort and 123/782 (15.7%) of our post–COVID-19 cohort who have provided a response to the Karnofsky Performance Status survey. These patients, who are house- or bed-bound, are underrepresented in traditional research settings.
**Figure 7.** Registry enrollment of adults with ME/CFS in the United States by state (as of September 30, 2021). Map based on longitude (generated) and latitude (generated). Each state with ME/CFS and control volunteers enrolled shows a color corresponding to enrollment count aggregated from zip code data provided by participants (N=2085). ME/CFS: myalgic encephalomyelitis/chronic fatigue syndrome; Registry: You + ME Registry and Biobank.

You + ME | ME/CFS: Enrollment in the U.S. by State (as of 9/30/21)

**Figure 8.** Registry enrollment of adult control volunteers in the United States by state (as of September 30, 2021). Map based on longitude (generated) and latitude (generated). Each state with participants enrolled shows a color corresponding to post–COVID-19 enrollment count aggregated from zip code data provided by the participants (N=387). ME: myalgic encephalomyelitis; Registry: You + ME Registry and Biobank.

You + ME | COVID: Enrollment in the U.S. by State (as of 9/30/21)
Figure 9. Registry enrollment of adults post–COVID-19 by country (as of September 30, 2021). Map based on longitude (generated) and latitude (generated). Each country with participants enrolled shows a color corresponding to post–COVID-19 enrollment count from country of residence data provided by the participants (N=836). ME: myalgic encephalomyelitis; Registry: You + ME Registry and Biobank.

Overall enrollment targets by cohort for the first 3 years of the Registry are summarized in Table 4. The goal is for 30% of the ME/CFS and post–COVID-19 cohorts to be controls (in the post–COVID-19 cohort, controls are individuals who had COVID-19 but fully recovered and never experienced LC). Another goal is for 25% of the entire Registry cohort to be based outside the United States by the end of year 3.

| Cohort       | Year 1 (N=3800), n (%) | Year 2 (N=9000), n (%) | Year 3 (N=15,000), n (%) |
|--------------|------------------------|------------------------|-------------------------|
| ME/CFS cohort<sup>b</sup> | 3000 (78.9)            | 7000 (77.8)            | 10,000 (66.7)           |
| LC<sup>d</sup> cohort<sup>e</sup> | 800 (21.1)             | 2000 (22.2)            | 5000 (33.3)             |

<sup>a</sup>Registry: You + ME Registry and Biobank.
<sup>b</sup>ME/CFS: myalgic encephalomyelitis/chronic fatigue syndrome.
<sup>c</sup>Includes control volunteers without ME/CFS.
<sup>d</sup>LC: long COVID.
<sup>e</sup>Includes controls (COVID-19-recovered).

Mobile App Engagement

According to an analysis completed in August 2021, 1358 participants (56.1% of those who had enrolled by the end of July 2021) with ME/CFS and LC had downloaded the mobile tracking app and over 1264 (93.1% of those who had downloaded the app) initiated tracking. Nearly half of the app users had tracked symptom and other health data on 10 or more days. Collectively, mobile app users had logged 38,242 tracking days. The days per week tracked by users (on average) showed high engagement (3-7 days per week) from a superuser group comprising 106 (8%) of users. In addition, 207 (16%) had moderate engagement (1-2 days per week), and three-quarters (n=951) had low engagement (less than 1 day per week); see Figure 10.
**Participant Satisfaction**

Of 172 participants who completed our community feedback survey as of September 30, 2021, 122 (70.9%) rated their overall satisfaction with the Registry as 7 or higher (on a scale of 1-10).

The Registry has qualified as “great” using a user satisfaction index measurement called a net promoter score, in which respondents are asked how likely they are to recommend it to a friend (see Figure 11).

**Discussion**

**Preliminary Results: Participant Enrollment and Satisfaction**

This paper describes the design, operation, recruitment, geographical coverage, and overall participant satisfaction for the Registry. With a plan to enroll a large and diverse cohort for longitudinal data collection, this data resource has the potential to improve the understanding of ME/CFS and LC, facilitate translational research, and inform clinical care and improve the quality of life for people living with ME/CFS and LC.

Resources such as the UK Biobank and other large-scale research efforts have demonstrated the power of large cohorts for biomedical discovery [48] and motivated our goal to collect data from tens of thousands of individuals. Enrollment in the Registry has been robust, with over 4000 participants registered within 2 years of opening; participant accrual and the trajectory toward enrollment targets have been consistent with similar online disease registries [15,16].

Compared to traditional, in-person studies, online studies and web-based recruitment can enable participation from people with diverse geography, backgrounds, and disease experiences [15-17]. The Registry has successfully enrolled some hard-to-reach participants, including people from nonurban areas.
areas and severely ill patients, who are house- or bed-bound. In addition to the convenience of online participation, strong enrollment in the Registry is likely driven by the broad eligibility criteria and highly motivated patient populations who want to contribute to research [49] that will help them and others, as has been observed in other disease registries.

Users have reported finding the mobile app useful for ongoing tracking of their symptoms and other factors, but use of the app is extremely variable. Others only use it for a limited period due to a multitude of factors, including the burden of frequent tracking, mobile app functionality (eg, periodic bugs or personal preferences around app functionality), or an aversion to being reminded of their health. Deploying strategies that encourage more frequent tracking with the app is an ongoing priority.

The high degree of satisfaction with both the data collection process and the digital tools reported by the You + ME community members reflects the incorporation of perspectives from multiple stakeholders into the Registry design and the benefits of cocreation and HCD in the development of digital health tools [28,50-52]. Facilitating a mechanism for those living with an illness to share the unique insights of their lived experience and partnering with them on the development of tools to capture that experience are best practices that should be universally adopted to improve our understanding and therapeutic development.

Participant satisfaction and commitment to the Registry will be key to continued success and further expansion. We learned from other efforts that a meaningful approach to maximizing retention and engagement in a research study over time is sharing individualized data and research results back [53,54]. You + ME registrants have access to the survey information they provide, as well as readouts of symptom data from the tracking app that provide a resource for self-management and sharing of information with health care providers and loved ones.

**Using the Data to Drive Research**

The overarching goal of the Registry is to serve as a catalyst for critical research into diagnostics, treatments, and cures for ME/CFS, LC, and other postinfection diseases using the power of a large cohort with prospectively collected data. The data collection combines patient-reported outcomes that are important to community members with validated scales. These data can be used for researching associations between numerous characteristics and disease courses and to validate outcome data reported by patients as benchmarks for future approval of treatments [15,16].

One of the benefits of this data set is the ability to look across cohorts to understand the similarities and differences between ME/CFS and LC. Cross-disease and disease subtype comparisons using data from registries have produced valuable insights, including clarification of clinical profiles and implication of targeted therapies [55,56]. The establishment of the Registry during the COVID-19 pandemic, during which case numbers have been highly concentrated over a short period, presented an opportunity to track and study trajectories of symptom improvement or worsening in a population with a singular infectious trigger. Clues about susceptibility and resilience to long-term effects of COVID-19 could also benefit the millions of Americans already diagnosed with ME/CFS [56].

The Registry has started to support data analysis by the internal research team and in partnership with external researchers. One example of active promotion of the Registry is through the Solve M.E. Ramsay Grant Program, an annual peer-reviewed competition for grants in support of pilot studies that first launched in 2016. In 2021, the Ramsay Grant Program opened a new funding mechanism to analyze Registry data, ultimately funding 2 projects [5].

To further increase accessibility and utility of the Registry research data set, we plan to build an interface that allows vetted researchers to query and use the data for a range of scientific projects. Researchers will be required to share their results so a community of researchers can further test the findings or build from them in new work.

**Limitations**

Despite these successes, the current Registry study design and data set has some limitations, including reliance on self-report data, which can produce a measurement error due to participant recall, interpretation, or other factors [57]. The Registry is also subject to selection bias, including sociodemographic and other differences between participants and nonparticipants, selective participant drop-off, and missing data. These are frequent concerns in registry-based research and introduce data accuracy, interpretation, and generalizability issues. We are therefore planning a number of actions to improve the representativeness of the Registry cohort and pursuing studies to evaluate our measurements, guide development of the protocol, and examine the quality and usefulness of the data.

**Engagement and Data Completeness**

Both ME/CFS and LC are illnesses that evolve and change over time. Although the Registry and symptom-tracking app are specifically designed to capture this, they are dependent on continued engagement from the Registry community, both within visits and over time. Data completeness, potential bias in completion rates, and data quality will be continuously monitored. Developing novel approaches for engagement and learning from others [50,52] who have successfully achieved this will be an ongoing priority.

**Diversifying the You + ME Community**

The Registry is predominantly made up of White non-Hispanic individuals. Ethnic minorities are underrepresented as participants in biomedical and public health research, due to a multitude of personal (eg, cultural distrust and perceptions of research), social (eg, expenses, work, and home responsibilities), and research-related (eg, inaccessibility of study documents and materials, travel to study locations) factors [58]. The use of online surveys that can be completed at home addresses some of these barriers to participation, but there are still reported ethnic and socioeconomic status (SES) differences in web-based research study participation [59]. In collaboration with partners, a directed effort will be made to increase Registry inclusivity
and participation and to develop strategies that address recruitment bias.

**Expanding Our Control Cohort**

The existing control cohort represents a little more than 10% of overall participants; the target is 30%. To ensure the control cohort is adequately matched on key demographic variables and therefore able to serve as a comparison group to our ME/CFS and LC cohorts, direct, targeted outreach and more innovative approaches, including partnership with other disease registries to share a control data set, will be explored.

**Next Steps for the Registry**

**Meeting the Needs of Adolescents**

Both ME/CFS and LC affect adolescents; this group is often underrepresented in clinical research [60-62]. The symptom clusters experienced by this population are often distinct from the adult population; for example, many adolescents with ME/CFS have OI as a predominant symptom [63,64].

Development of a version of the Registry for adolescents aged 13-17 years is currently underway. It will be designed specifically for this age group, so it includes an appropriate consent and data collection process.

**Biosample Collection**

To accompany the rich longitudinal phenotypic data collected in the Registry, biological samples will be collected from a subset of the larger Registry cohort to both support specific research projects and create a biorepository of samples for future research. Samples will include 1 or more of the following:

- Dried blood spot (DBS) cards (DNA, RNA, protein expression, and metabolomics analyses)
- Dried urine strips (DUS; metabolomics)
- Fecal samples for analyses of microbiome composition and metagenomics (determination of potential microbial metabolites that affect gastrointestinal, immune, metabolic, neurologic, and systemic health)
- Saliva (salivary biomarkers)
- Venipuncture blood draw, and processing and storage of blood components (immunologic, metabolomics, microbiome/virome)

These sample types can support a range of research and make up the immediate biosample collection protocol, but studying other tissue types, such as cerebrospinal fluid, is possible in the future. Samples will be stored by a certified good clinical practice (GCP) provider indefinitely in the Solve M.E. Biobank but destroyed upon request if a participant withdraws.

**Expanding the Registry to Integrate New Data Types**

Although the current capabilities of the Registry can support expansive data collection, the platform is also built with the capacity to integrate new data types (eg, passive monitoring from wearables and health care data from participants’ clinicians). This gives great potential for multimodal data, in particular physiological data, that can be combined with self-reported data to significantly increase the accuracy and validity of results and to reduce bias.

**Acknowledgments**

We are incredibly grateful to the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID (LC) community members who have continually contributed insights and ideas for the You + ME Registry and Biobank (Registry), helped to design the data collection process, spent hours testing the platform and mobile app, and spent extensive time and energy enrolling and completing surveys.

Special thanks also go to Rochelle Joslyn (PhD), Rachael Carder, and Beth Mazur for their wisdom and expert advice on numerous aspects of the Registry design and data collection process.

We are deeply appreciative of the scientists and clinicians who provided advice and input, particularly Anthony L Komaroff (MD), and others in the field who shared their protocols for data collection so we could work to harmonize data: Jarred Younger (PhD), Luis Nacul (MD, PhD), Eliana Lacerda (MD, PhD), Lucinda L Bateman (MD), and Nancy Klimas (MD), to name a few.

We are incredibly grateful to our partners at Topflight Apps, who partnered with us on the development of the Registry platform, with particular thanks to Francesco Mantovani and Alex Lorincz for their dedication and creativity.

Thank you to the UK ME/CFS Biobank (UKMEB) and CureME team and the London School of Hygiene and Tropical Medicine for licensing their Symptoms Assessment and scoring algorithm to the Registry.

This work would not be possible without funding from countless individual donors to the Solve ME/CFS Initiative (Solve M.E.). The development of the Registry database and mobile app was supported in part by the National Institutes of Health (NIH) grant U24-NS-105535 as part of the ME/CFS Collaborative Research Network.

**Authors’ Contributions**

Conceptualization was performed by SW and AR; data curation by ES and AR; visualization by KM and AR; and drafting of the manuscript by KM, AR, and SW. All authors have approved the final draft of this manuscript.

**Conflicts of Interest**

None declared.
References

1. Valdez AR, Hancock EE, Adebayo S, Kiernicki DJ, Proskauer D, Attewell JR, et al. Estimating prevalence, demographics, and costs of ME/CFS using large scale medical claims data and machine learning. Front Pediatr 2018 Jan 8;6:412 [FREE Full text] [doi: 10.3389/fped.2018.000412] [Medline: 30671425]

2. Jason L, Mirin A. Updating the National Academy of Medicine ME/CFS prevalence and economic impact figures to account for population growth and inflation. Fatigue: Biomed Health Behav 2021 Jan 28;9(1):9-13 [FREE Full text] [doi: 10.1080/21641846.2021.1878716]

3. Cortes Rivera M, Mastronard C, Silva-Aldana C, Arcos-Burgos M, Lidbury B. Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics (Basel) 2019 Aug 07;9(3):91 [FREE Full text] [doi: 10.3390/diagnostics9030091] [Medline: 31394725]

4. Collin SM, Bakken IJ, Nazareth I, Crawley E, White PD. Trends in the incidence of chronic fatigue syndrome and fibromyalgia in the UK, 2001-2013: a Clinical Practice Research Datalink study. J R Soc Med 2017 Jun;110(6):231-244 [FREE Full text] [doi: 10.1177/014107617702530] [Medline: 28358988]

5. Solve ME/CFS Initiative. About the Ramsay Grant Program. URL: https://solvemecfs.org/research-and-registry/ramsay-research-grants/ [accessed 2022-07-14]

6. Siegel SD, Antoni MH, Fletcher MA, Maher K, Segota MC, Klimas N. Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: preliminary evidence for a subgroup? J Psychosom Res 2006 Jun;60(6):559-566 [FREE Full text] [doi: 10.1016/j.jpsychores.2006.03.001] [Medline: 16731230]

7. Bansal A, Bradley A, Bishop K, Kiani-Alkhan A, Ford B. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun 2012 Jan;26(1):24-31 [FREE Full text] [doi: 10.1016/j.bbi.2011.06.016]

8. Strayer DR, Young D, Mitchell WM. Effect of disease duration in a randomized phase III trial of rintatolimod, an immune modulator for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Front Immunol 2019 Apr 16;10:796 [FREE Full text] [doi: 10.3389/fimmu.2019.00796] [Medline: 31057538]

9. Sweetman E, Noble A, Edgar C, Mackay A, Hellwell A, Vallings R, et al. Current research provides insight into the biological basis and diagnostic potential for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Diagnostics (Basel) 2019 Jul 10;9(3):73 [FREE Full text] [doi: 10.3390/diagnostics9030073] [Medline: 31295930]

10. Chang S, Liew P, Ansar M, Lin S, Wang S, Hung C, et al. Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction. Clin Epigenet 2020 May 12;12(1):67 [FREE Full text] [doi: 10.1186/s13477-020-00055-z] [Medline: 32398064]

11. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. Occup Med (Lond) 2005 Jan;55(1):20-31 [FREE Full text] [doi: 10.1093/occmed/kqi013] [Medline: 15699087]

12. Strayer DR, Young D, Mitchell WM. Effect of disease duration in a randomized phase III trial of rintatolimod, an immune modulator for myalgic encephalomyelitis/chronic fatigue syndrome. PLoS One 2020 Oct 29;15(10):e0240403 [FREE Full text] [doi: 10.1371/journal.pone.0240403]

13. Fluge Ø, Rekeland IG, Lien K, Th, et al. B-lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Front Immunol 2019 Apr 16;10:796 [FREE Full text] [doi: 10.3389/fimmu.2019.00796] [Medline: 31057538]

14. Lattie EG, Antoni MH, Fletcher MA, Czaja S, Perdomo D, Sala A, et al. Beyond myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) symptom severity: stress management skills are related to lower illness burden. Fatigue 2013 Oct;11(5):495-503 [FREE Full text] [doi: 10.7326/m13-1451]

15. Smolensky L, Amondakar N, Crawford K, Neu S, Kopil C, Daeschler M. Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson's disease. Sci Data 2020 Feb 24;7(1):67 [FREE Full text] [doi: 10.1038/s41597-020-00855-z]

16. Lappin CM, Kappelman MD, Martin CF, Lewis JD, Mayer L, Kninene PM, et al. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis 2012 Nov;18(11):2099-2106 [FREE Full text] [doi: 10.1002/ibd.22895] [Medline: 22287300]

17. Pierson SK, Khor JS, Ziglar J, Liu A, Floess K, NaPier E, et al. ACCELERATE: a patient-powered natural history study design enabling clinical and therapeutic discoveries in a rare disorder. Cell Rep Med 2020 Dec 22;1(4):210-222 [FREE Full text] [doi: 10.1016/j.xcrm.2020.100158] [Medline: 33377129]

18. A Registry for the ME/CFS + Long Covid Communities. URL: https://youandmereregistry.com/ [accessed 2022-07-14]

19. Zhou Z, Kang H, Li S, Zhao X. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotrophic mechanisms. J Neurol 2020 Aug 26;267(8):2179-2184 [FREE Full text] [doi: 10.1007/s00415-020-09929-7] [Medline: 32458193]

20. Román GC, Spencer PS, Reis J, Buguet A, Faris MEA, Katrak SM, WFN Environmental Neurology Specialty Group. The neurology of COVID-19 revisited: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. J Neurol Sci 2020 Jul 15;414:116884 [FREE Full text] [doi: 10.1016/j.jns.2020.116884] [Medline: 32464367]
21. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol 2011 Mar 24;11(1):37 [FREE Full text] [doi: 10.1186/1471-2377-11-37] [Medline: 21435231]

22. Collins F. NIH Launches New Initiative to Study “Long COVID”. URL: https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid [accessed 2022-07-14]

23. Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services. BMC Health Serv Res 2020 Dec 20;20(1):1144 [FREE Full text] [doi: 10.1186/s12913-020-00600-y] [Medline: 33342437]

24. Göertz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020 Oct;6(4):00542-2020 [FREE Full text] [doi: 10.1183/23120541.00542-2020] [Medline: 33257910]

25. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021 Aug;38:101019 [FREE Full text] [doi: 10.1016/j.eclinm.2021.101019] [Medline: 34308300]

26. Treluand J. Long COVID – We’ve Been Here Before. URL: https://www.bma.org.uk/news-and-opinion/long-covid-we-ve-been-here-before [accessed 2022-07-14]

27. Topol E, Verghese A, Fauci A. “We’re All in It Together and We’re Gonna Get Through It”. URL: https://www.washingtonpost.com/world/2021/05/17/topol-verghese-fauci/ [accessed 2022-07-14]

28. Holeman I, Kane D. Human-centered design for global health equity. Inf Technol Dev 2019 Sep 29;26(3):477-505 [FREE Full text] [doi: 10.1080/02681102.2019.1667289] [Medline: 32982007]

29. Flood M, Ennis M, Ludlow A, Sweeney FF, Holton A, Morgan S, et al. Research methods from human-centered design: potential applications in pharmacy and health services research. Res Social Adm Pharm 2021 Dec;17(12):2036-2043 [FREE Full text] [doi: 10.1016/j.sapharm.2021.06.015] [Medline: 34229952]

30. Giacomini J. What is human centred design? Design J 2015 Apr 28;17(4):606-623. [doi: 10.2752/175630614X1405618548186]

31. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol 2011 Mar 24;11(1):37 [FREE Full text] [doi: 10.1186/1471-2377-11-37] [Medline: 21435231]

32. MongoDB. URL: https://www.mongodb.com/ [accessed 2022-07-14]

33. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Data Standards. URL: https://www.commondataelements.ninds.nih.gov/Myalgic%20Encephalomyelitis/Chronic%20Fatigue%20Syndrome [accessed 2022-07-14]

34. Lupton D. Social Media, Activism, Trucker Caps: The Fascinating Story behind Long COVID. URL: https://theconversation.com/social-media-activism-trucker-caps-the-fascinating-story-behind-long-covid-168465 [accessed 2022-07-14]

35. What Is ME/CFS?. URL: https://mefsc linicancoalition.org/about-mefs/ [accessed 2022-07-14]

36. Centers for Disease Control and Prevention (CDC). Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: What is ME/CFS?. URL: https://www.cdc.gov/me-cfs/about/index.html [accessed 2022-07-14]

37. Lacerda EM, Bowman EW, Cliff JM, Kingdon CC, King EC, Lee J, et al. The UK ME/CFS Biobank for biomedical research on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and multiple sclerosis. Open J Bioresour 2017;4:4 [FREE Full text] [doi: 10.5334/ojbr.28]

38. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994 Dec 15;121(12):953-959. [doi: 10.7326/0003-4819-121-12-199412150-00009] [Medline: 7978722]

39. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. Myalgic encephalomyelitis/chronic fatigue syndrome. J Chronic Fatigue Syndr 2011 Dec 04;11(1):7-115 [FREE Full text] [doi: 10.1300/J092v11n01_02]

40. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med 2011 Oct;270(4):327-338 [FREE Full text] [doi: 10.1111/j.1365-2769.2011.02428.x] [Medline: 21777306]

41. Institute of Medicine of the National Academies. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press; 2015.

42. Sharpe MC, Archard LC, Banatvala JE, Borisyewicz LK, Clare AW, David A, et al. A report--chronic fatigue syndrome: guidelines for research. J R Soc Med 1991 Feb;84(2):118-121 [FREE Full text] [Medline: 1999813]

43. Modie K, Estévez-López F, Sekulic S, Ivanovs A, Sepulveda N, Zalewski P. Recommendations for epidemiological research in ME/CFS from the EUROMENE Epidemiology Working Group. Preprints [FREE Full text] [doi: 10.20944/preprints202009.0744.v1]

44. Ware J, Sherbourne C. User's Manual for the SF-36v2 Health Survey Second Edition. Lincoln, RI: QualityMetric; 2007.

45. Ferrucci L, Koh C, Bandinelli S, Guralnik J. Disability, functional status, and activities of daily living. In: Encyclopedia of Gerontology. Amsterdam, the Netherlands: Elsevier B.V; 2007:427-436.

46. Shahid A, Wilkinson K, Marcu S, Shapiro C. STOP, THAT and One Hundred Other Sleep Scales. Berlin: Springer Science+Business Media; 2012.
47. Smets E, Garsen B, Bonke B, De Haes J. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995 Apr;39(3):315-325. [doi: 10.1016/0022-3999(94)00125-0]

48. Lacerda EM, Mudie K, Kingdom CC, Butterworth JD, O'Boyle S, Nacul L. The UK ME/CFS Biobank: a disease-specific biobank for advancing clinical research into myalgic encephalomyelitis/chronic fatigue syndrome. Front Neurol 2018 Dec;9(12):1026 [FREE Full text] [doi: 10.3389/fneur.2018.01026] [Medline: 30564186]

49. Solomon DH, Shadick NA, Weinblatt ME, Frits M, Iannaccone C, Zak A, et al. Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries. BMC Med Res Methodol 2017 Apr 17;17(1):59 [FREE Full text] [doi: 10.1186/s12874-017-0343-3] [Medline: 28415991]

50. Fagotto E. Engaging Patients for Research that Matters: IBD Partners. URL: https://ash.harvard.edu/publications/engaging-patients-research-matters-ibd-partners [accessed 2022-07-14]

51. Fleisher L, Bass SB, Shwarz M, Washington A, Nicholson A, Alhajji M, et al. Using theory and user-centered design in digital health: the development of the mychoice communication tool to prepare patients and improve informed decision making regarding clinical trial participation. Psychooncology 2020 Jan 02:29(1):114-122. [doi: 10.1002/pon.5254] [Medline: 31654442]

52. Azeez-Narain K. Can Human-Centered Design Help Create Better Digital Health Solutions?. URL: https://www.healthtechmagazines.com/can-human-centered-design-help-create-better-digital-health-solutions/ [accessed 2022-07-14]

53. All of Us Research Program Investigators. The “All of Us” research program. N Engl J Med 2019 Aug 15;381(7):668-676 [FREE Full text] [doi: 10.1056/nejmsr1809937]

54. Nelson EC, Dixon-Woods M, Batalden PB, Hom A, Van Citters AD, Morgan TS, et al. Patient focused registries can improve health, care, and science. BMJ 2016 Jul 01;354:i3319 [FREE Full text] [doi: 10.1136/bmj.i3319] [Medline: 27370543]

55. Inwald EC, Koller M, Klinikhammer-Schalke M, Zeman H, Hofst... [FREE Full text] [Medline: 26369534]

56. Fereshtehnejad S, Damangir S, Cermakova P, Aarsland D, Eriksdotter M, Religa D. Comorbidity profile in dementia with Lewy bodies versus Alzheimer's disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry. Alzheimers Res Ther 2014 Oct 6;6(5-8):65 [FREE Full text] [doi: 10.1186/s13195-014-0065-2] [Medline: 25478027]

57. Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc 2016 May;11. [doi: 10.2147/jmdh.s104870]

58. Yancey AK, Ortega AN, Kumanyika SK. Effective recruitment and retention of minority research participants. Annu Rev Public Health 2006 Apr 01;27(1):1-28 [FREE Full text] [doi: 10.1146/annurev.publhealth.27.021405.102113] [Medline: 16533107]

59. Jang M, Vorderstrasse A. Socioeconomic status and racial or ethnic differences in participation: web-based survey. JMI... [FREE Full text] [doi: 10.2196/jmir.11865] [Medline: 30969173]

60. Grady C, Wiener L, Abdoler E, Trauernicht E, Zadeh S, Diekema DS, et al. Assent in research: the voices of adolescents. J Adolesc Health 2014 May;54(5):515-520 [FREE Full text] [doi: 10.1016/j.jadohealth.2014.02.005] [Medline: 24630932]

61. Brown DL, Cowdry JE, Jones TS, Langford A, Gamage C, Jacobs TL. Adolescent knowledge and attitudes related to clinical trials. Clin Trials 2015 Jun 10;12(3):212-214 [FREE Full text] [doi: 10.1177/1740774515571443] [Medline: 25673637]

62. American College of Obstetricians and Gynecologists. Guidelines for Adolescent Health Research - Committee Opinion No 665. URL: https://www.acog.orgclinical/counseling-guidance/committee-opinion/articles/2016/06/guidelines-for-adolescent-health-research [accessed 2022-07-14]

63. Jason LA, Benton MC, Valentine L, Johnson A, Torres-Harding S. The economic impact of ME/CFS: individual and societal costs. Dyn Med 2008 Apr 08;7(1):6 [FREE Full text] [doi: 10.1186/1476-5918-7-6] [Medline: 18397528]

64. Jason LA, Katz BZ, Sunquist M, Torres C, Cotler J, Bhatia S. The prevalence of pediatric myalgic encephalomyelitis/chronic fatigue syndrome in a community-based sample. Child Youth Care Forum 2020 Aug 23;49(4):563-579 [FREE Full text] [doi: 10.1007/s10566-019-09543-3] [Medline: 34113066]

Abbreviations

HCD: human-centered design
LC: long COVID
ME/CFS: myalgic encephalomyelitis/chronic fatigue syndrome
OI: orthostatic intolerance
PEM: postexertional malaise
Registry: You + ME Registry and Biobank
Solve M.E.: Solve ME/CFS Initiative
UKMEB: UK ME/CFS Biobank

Edited by T Leung; submitted 26.01.22; peer-reviewed by J Seitz, C Jacob; comments to author 27.04.22; revised version received 03.06.22; accepted 05.06.22; published 10.08.22

Please cite as:
Ramiller A, Mudie K, Seibert E, Whittaker S
The Facilitation of Clinical and Therapeutic Discoveries in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Related Diseases: Protocol for the You + ME Registry Research Platform
JMIR Res Protoc 2022;11(8):e36798
URL: https://www.researchprotocols.org/2022/8/e36798
doi: 10.2196/36798
PMID: 35816681

©Allison Ramiller, Kathleen Mudie, Elle Seibert, Sadie Whittaker. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 10.08.2022. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.